Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)
- 389 Downloads
Dehydroepiandrosterone (DHEA) is helpful for treating vaginal symptoms. This secondary analysis evaluated the impact of vaginal DHEA on hormone concentrations, bone turnover, and vaginal cytology in women with a cancer history.
Postmenopausal women, diagnosed with breast or gynecologic cancer, were eligible if they reported at least moderate vaginal symptoms. Participants could be on tamoxifen or aromatase inhibitors (AIs). Women were randomized to 3.25 versus 6.5 mg/day of DHEA versus a plain moisturizer (PM) control. Sex steroid hormone levels, biomarkers of bone formation, vaginal pH, and maturation index were collected at baseline and 12 weeks. Analysis included independent t tests and Wilcoxon rank tests, comparing each DHEA arm with the control.
Three hundred forty-five women contributed evaluable blood and 46 contributed evaluable cytology and pH values. Circulating DHEA-S and testosterone levels were significantly increased in those on vaginal DHEA in a dose-dependent manner compared to PM. Estradiol was significantly increased in those on 6.5 mg/day DHEA but not in those on 3.25 mg/day DHEA (p < 0.05 and p = 0.05, respectively), and not in those on AIs. Biomarkers of bone formation were unchanged in all arms. Maturation of vaginal cells was 100% (3.25 mg/day), 86% (6.5 mg/day), and 64% (PM); pH decreased more in DHEA arms.
DHEA resulted in increased hormone concentrations, though still in the lowest half or quartile of the postmenopausal range, and provided more favorable effects on vaginal cytology, compared to PM. Estrogen concentrations in women on AIs were not changed. Further research on the benefit of vaginal DHEA is warranted in hormone-dependent cancers.
KeywordsVaginal dehydroepiandrosterone Vaginal symptoms Postmenopause
This work was supported by the National Cancer Institute of the National Institutes of Health (grant UG1CA189823, to the Alliance for Clinical Trials in Oncology NCORP Grant) and also in part by the Public Health Service (grants U10CA025224, U10CA035090, U10CA035101, U10CA035103, U10CA035113, U10CA035119, U10CA035267, U10CA035269, U10CA035415, U10CA035431, U10CA035448, U10CA037404, U10CA037417, U10CA052352, U10CA063848, U10CA063849, U10CA180790, UG1CA189863, and UG1CA189971). This work was also supported in part by funds from a grant from the Breast Cancer Research Foundation.
Compliance with ethical standards
Conflict of interest
This study was supported by the National Cancer Institute and the Breast Cancer Research Foundation. None of the authors have any conflicts of interest with either of these two funding agencies. The work is solely that of the authors and does not reflect the views of the funding agencies. The data is under the control of the Statistics and Data Management group of the Alliance and can be produced in support of the analysis described in this paper, if required.
- 3.Ganz PA, Cecchini RS, Julian TB et al (2016) Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387(10021):857–865CrossRefPubMedGoogle Scholar
- 10.North American Menopause Society (2007) The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause (New York) 14(3 Pt 1):355–369 quiz 370–351Google Scholar
- 13.Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, Hayes DF, Decker DA (2012) Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 8(3):144–148. https://doi.org/10.1200/JOP.2011.000352 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, Members of the VVA Prasterone Research Group (2015) Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med 12(12):2401–2412. https://doi.org/10.1111/jsm.13045 CrossRefPubMedGoogle Scholar
- 21.Samaras N, Samaras D, Frangos E, Forster A, Philippe JA (2013) Review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial? Rejuvenation Res 16(4):285–294. https://doi.org/10.1089/rej.2013.1425 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Tuntiviriyapun P, Panyakhamlerd K, Triratanachat S, Chatsuwan T, Chaikittisilpa S, Jaisamrarn U, Taechakraichana N (2015) Newly developed vaginal atrophy symptoms II and vaginal pH: a better correlation in vaginal atrophy? Climacteric 18(2):246–251. https://doi.org/10.3109/13697137.2014.981520 CrossRefPubMedGoogle Scholar
- 27.Barton DL, Sloan JA, Shuster LT, et al Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance), J Clin Oncol, 2014 ASCO Annual Meeting Abstracts. Vol 32 No 15_suppl (May 20 Supplement), 2014: 9507Google Scholar
- 30.Traish AM, Fetten K, Miner M, Hansen ML, Guay A (2010) Testosterone and risk of breast cancer: appraisal of existing evidence. Horm Mol Biol Clin Invest 2(1):177–190Google Scholar